Skip to main content
Top
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Parkinson's Disease | Study Protocol

Transforming Parkinson's Care in Africa (TraPCAf): protocol for a multimethodology National Institute for Health and Care Research Global Health Research Group project

Authors: R. Walker, N. Fothergill-Misbah, S. Kariuki, O. Ojo, R. Cilia, M. C. J. Dekker, O. Agabi, A. Akpalu, F. Amod, M. Breckons, M. Cham, S. Del Din, C. Dotchin, S. Guggsa, J. Kwasa, D. Mushi, F. O. Nwaokorie, T. Park, L. Rochester, J. Rogathi, F. S. Sarfo, A. Shalash, L. Ternent, S. Urasa, N. Okubadejo

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

Parkinson’s disease (PD) is the second most common neurodegenerative disorder and, according to the Global Burden of Disease estimates in 2015, was the fastest growing neurological disorder globally with respect to associated prevalence, disability, and deaths. Information regarding the awareness, diagnosis, phenotypic characteristics, epidemiology, prevalence, risk factors, treatment, economic impact and lived experiences of people with PD from the African perspective is relatively sparse in contrast to the developed world, and much remains to be learned from, and about, the continent.

Methods

Transforming Parkinson’s Care in Africa (TraPCAf) is a multi-faceted, mixed-methods, multi-national research grant. The study design includes multiple sub-studies, combining observational (qualitative and quantitative) approaches for the epidemiological, clinical, risk factor and lived experience components, as appropriate, and interventional methods (clinical trial component). The aim of TraPCAf is to describe and gain a better understanding of the current situation of PD in Africa. The countries included in this National Institute for Health and Care Research (NIHR) Global Health Research Group (Egypt, Ethiopia, Ghana, Kenya, Nigeria, South Africa and Tanzania) represent diverse African geographies and genetic profiles, with differing resources, healthcare systems, health and social protection schemes, and policies. The research team is composed of experts in the field with vast experience in PD, jointly led by a UK-based and Africa-based investigator.

Discussion

Despite the increasing prevalence of PD globally, robust data on the disease from Africa are lacking. Existing data point towards the poor awareness of PD and other neurological disorders on the continent and subsequent challenges with stigma, and limited access to affordable services and medication. This multi-site study will be the first of its kind in Africa. The data collected across the proposed sub-studies will provide novel and conclusive insights into the situation of PD. The selected country sites will allow for useful comparisons and make results relevant to other low- and middle-income countries. This grant is timely, as global recognition of PD and the public health challenge it poses builds. The work will contribute to broader initiatives, including the World Health Organization’s Intersectoral global action plan on epilepsy and other neurological disorders.
Appendix
Available only for authorised users
Literature
2.
go back to reference World Health Organization: Web-based consultation on the first draft of the Intersectoral Global Action Plan on epilepsy and other neurological disorders 2022–2031. In. Geneva; 2021. World Health Organization: Web-based consultation on the first draft of the Intersectoral Global Action Plan on epilepsy and other neurological disorders 2022–2031. In. Geneva; 2021.
3.
go back to reference Schiess N, Cataldi R, Okun MS, Fothergill-Misbah N, Dorsey ER, Bloem BR, Barretto M, Bhidayasiri R, Brown R, Chishimba L et al: Six Action Steps to Address Global Disparities in Parkinson Disease: A World Health Organization Priority. JAMA Neurology 2022. Schiess N, Cataldi R, Okun MS, Fothergill-Misbah N, Dorsey ER, Bloem BR, Barretto M, Bhidayasiri R, Brown R, Chishimba L et al: Six Action Steps to Address Global Disparities in Parkinson Disease: A World Health Organization Priority. JAMA Neurology 2022.
4.
go back to reference Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, Ansha MG, Brayne C, Choi J-YJ, Collado-Mateo D, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–53. Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, Ansha MG, Brayne C, Choi J-YJ, Collado-Mateo D, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939–53.
5.
go back to reference GBD 2016 Neurology Collaborators: Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 2019, 18(5):459–480. GBD 2016 Neurology Collaborators: Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology 2019, 18(5):459–480.
6.
go back to reference Bloem BR, Okun MS, Klein C. Parkinson’s disease. The Lancet. 2021;397(10291):2284–303. Bloem BR, Okun MS, Klein C. Parkinson’s disease. The Lancet. 2021;397(10291):2284–303.
7.
go back to reference Mshana G, Dotchin CL, Walker RW. “We call it the shaking illness”: perceptions and experiences of Parkinson’s disease in rural northern Tanzania. BMC Public Health. 2011;11(219):1–8. Mshana G, Dotchin CL, Walker RW. “We call it the shaking illness”: perceptions and experiences of Parkinson’s disease in rural northern Tanzania. BMC Public Health. 2011;11(219):1–8.
8.
go back to reference Fothergill-Misbah N. The lived experience of stigma and parkinson’s disease in Kenya: a public health challenge. BMC Public Health. 2023;23(1):364.PubMedPubMedCentral Fothergill-Misbah N. The lived experience of stigma and parkinson’s disease in Kenya: a public health challenge. BMC Public Health. 2023;23(1):364.PubMedPubMedCentral
9.
go back to reference Dekker MCJ, Coulibaly T, Bardien S, Ross OA, Carr J, Komolafe M. Parkinson’s Disease research on the African continent: obstacles and opportunities. Front Neurol. 2020;11:512.PubMedPubMedCentral Dekker MCJ, Coulibaly T, Bardien S, Ross OA, Carr J, Komolafe M. Parkinson’s Disease research on the African continent: obstacles and opportunities. Front Neurol. 2020;11:512.PubMedPubMedCentral
10.
go back to reference Fothergill-Misbah N, Walker R, Kwasa J, Hooker J, Hampshire K. “Old people problems”, uncertainty and legitimacy: Challenges with diagnosing Parkinson’s disease in Kenya. Soc Sci Med. 2021;282: 114148.PubMed Fothergill-Misbah N, Walker R, Kwasa J, Hooker J, Hampshire K. “Old people problems”, uncertainty and legitimacy: Challenges with diagnosing Parkinson’s disease in Kenya. Soc Sci Med. 2021;282: 114148.PubMed
11.
go back to reference Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(10):2731–42.PubMedPubMedCentral Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(10):2731–42.PubMedPubMedCentral
12.
go back to reference Cilia R, Cereda E, Akpalu A, Sarfo FS, Cham M, Laryea R, Obese V, Oppon K, Del Sorbo F, Bonvegna S, et al. Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa. Brain. 2020;143(8):2490–501.PubMedPubMedCentral Cilia R, Cereda E, Akpalu A, Sarfo FS, Cham M, Laryea R, Obese V, Oppon K, Del Sorbo F, Bonvegna S, et al. Natural history of motor symptoms in Parkinson’s disease and the long-duration response to levodopa. Brain. 2020;143(8):2490–501.PubMedPubMedCentral
13.
go back to reference Williams U, Bandmann O, Walker R. Parkinson’s Disease in Sub-Saharan Africa: a review of epidemiology, genetics and access to care. J Mov Disord. 2018;11(2):53–64.PubMedPubMedCentral Williams U, Bandmann O, Walker R. Parkinson’s Disease in Sub-Saharan Africa: a review of epidemiology, genetics and access to care. J Mov Disord. 2018;11(2):53–64.PubMedPubMedCentral
14.
go back to reference Quarshie JT, Mensah EN, Quaye O, Aikins AR. The Current State of Parkinsonism in West Africa: a systematic review. Parkinson’s Disease. 2021;2021:7479423.PubMedPubMedCentral Quarshie JT, Mensah EN, Quaye O, Aikins AR. The Current State of Parkinsonism in West Africa: a systematic review. Parkinson’s Disease. 2021;2021:7479423.PubMedPubMedCentral
15.
go back to reference Blanckenberg J, Bardien S, Glanzmann B, Okubadejo NU, Carr JA. The prevalence and genetics of Parkinson’s disease in sub-Saharan Africans. J Neurol Sci. 2013;335(1–2):22–5.PubMed Blanckenberg J, Bardien S, Glanzmann B, Okubadejo NU, Carr JA. The prevalence and genetics of Parkinson’s disease in sub-Saharan Africans. J Neurol Sci. 2013;335(1–2):22–5.PubMed
16.
go back to reference World Health Organization. Parkinson disease: a public health approach. Geneva: Technical Brief. In; 2022. World Health Organization. Parkinson disease: a public health approach. Geneva: Technical Brief. In; 2022.
17.
go back to reference Dotchin C, Msuya O, Kissima J, Massawe J, Mhina A, Moshy A, Aris E, Jusabani A, Whiting D, Masuki G, et al. The prevalence of Parkinson’s disease in rural Tanzania. Mov Disord. 2008;23(11):1567–672.PubMed Dotchin C, Msuya O, Kissima J, Massawe J, Mhina A, Moshy A, Aris E, Jusabani A, Whiting D, Masuki G, et al. The prevalence of Parkinson’s disease in rural Tanzania. Mov Disord. 2008;23(11):1567–672.PubMed
18.
go back to reference Hamid E, Ayele BA, Massi DG, Ben Sassi S, Tibar H, Djonga EE, El-Sadig SM, El Khedoud AW, Razafimahefa J, Kouame-Assouan AE et al: Availability of therapies and services for Parkinson's Disease in Africa: a continent-wide survey. Mov Disord 2021, n/a(n/a). Hamid E, Ayele BA, Massi DG, Ben Sassi S, Tibar H, Djonga EE, El-Sadig SM, El Khedoud AW, Razafimahefa J, Kouame-Assouan AE et al: Availability of therapies and services for Parkinson's Disease in Africa: a continent-wide survey. Mov Disord 2021, n/a(n/a).
19.
go back to reference World Health Organization (WHO): Atlas: country resources for neurological disorders - 2nd ed. In. Geneva: World Health Organization,; 2017. World Health Organization (WHO): Atlas: country resources for neurological disorders - 2nd ed. In. Geneva: World Health Organization,; 2017.
20.
go back to reference Kaddumukasa M, Kakooza A, Kaddumukasa MN, Ddumba E, Mugenyi L, Sajatovic M, Katabira E. Knowledge and attitudes of Parkinson’s Disease in Rural and Urban Mukono District, Uganda: a cross-sectional. Community-Based Study Parkinson’s Disease. 2015;2015(196150):1–7. Kaddumukasa M, Kakooza A, Kaddumukasa MN, Ddumba E, Mugenyi L, Sajatovic M, Katabira E. Knowledge and attitudes of Parkinson’s Disease in Rural and Urban Mukono District, Uganda: a cross-sectional. Community-Based Study Parkinson’s Disease. 2015;2015(196150):1–7.
21.
go back to reference Mokaya J, Gray WK, Carr J. Beliefs, knowledge and attitudes towards Parkinson’s disease among a Xhosa speaking black population in South Africa: a cross-sectional study. Parkinsonism Relat Disord. 2017;41:51–7.PubMed Mokaya J, Gray WK, Carr J. Beliefs, knowledge and attitudes towards Parkinson’s disease among a Xhosa speaking black population in South Africa: a cross-sectional study. Parkinsonism Relat Disord. 2017;41:51–7.PubMed
22.
go back to reference Trivedi DK, Sinclair E, Xu Y, Sarkar D, Walton-Doyle C, Liscio C, Banks P, Milne J, Silverdale M, Kunath T, et al. Discovery of volatile biomarkers of Parkinson’s disease from Sebum. ACS Cent Sci. 2019;5(4):599–606.PubMedPubMedCentral Trivedi DK, Sinclair E, Xu Y, Sarkar D, Walton-Doyle C, Liscio C, Banks P, Milne J, Silverdale M, Kunath T, et al. Discovery of volatile biomarkers of Parkinson’s disease from Sebum. ACS Cent Sci. 2019;5(4):599–606.PubMedPubMedCentral
23.
go back to reference Cubo E, Doumbe J, Njiengwe E, Onana P, Garoña R, Alcalde J, Seco J, Mariscal N, Epundugu BM, Cubo S, et al. A Parkinson’s disease tele-education program for health care providers in Cameroon. J Neurol Sci. 2015;357(1–2):285–7.PubMed Cubo E, Doumbe J, Njiengwe E, Onana P, Garoña R, Alcalde J, Seco J, Mariscal N, Epundugu BM, Cubo S, et al. A Parkinson’s disease tele-education program for health care providers in Cameroon. J Neurol Sci. 2015;357(1–2):285–7.PubMed
24.
go back to reference Shalash A, Spindler M, Cubo E. Global perspective on telemedicine for Parkinson’s Disease. J Parkinsons Dis. 2021;11:S11–8.PubMedPubMedCentral Shalash A, Spindler M, Cubo E. Global perspective on telemedicine for Parkinson’s Disease. J Parkinsons Dis. 2021;11:S11–8.PubMedPubMedCentral
25.
go back to reference Dotchin CL, Msuya O, Walker RW. The challenge of Parkinson’s disease management in Africa. Age Ageing. 2007;36(2):122–7.PubMed Dotchin CL, Msuya O, Walker RW. The challenge of Parkinson’s disease management in Africa. Age Ageing. 2007;36(2):122–7.PubMed
26.
go back to reference Mokaya J, Dotchin CL, Gray WK, Hooker J, Walker RW. The Accessibility of Parkinson’s Disease Medication in Kenya: Results of a National Survey. Mov Disord Clin Pract. 2016;3(4):376–81.PubMedPubMedCentral Mokaya J, Dotchin CL, Gray WK, Hooker J, Walker RW. The Accessibility of Parkinson’s Disease Medication in Kenya: Results of a National Survey. Mov Disord Clin Pract. 2016;3(4):376–81.PubMedPubMedCentral
27.
go back to reference Okubadejo NU, Ojo OO, Wahab KW, Abubakar SA, Obiabo OY, Salawu FK, Nwazor EO, Agabi OP, Oshinaike OO. A nationwide survey of Parkinson’s disease medicines availability and affordability in Nigeria. Mov Disord Clin Pract. 2019;6(1):27–33.PubMed Okubadejo NU, Ojo OO, Wahab KW, Abubakar SA, Obiabo OY, Salawu FK, Nwazor EO, Agabi OP, Oshinaike OO. A nationwide survey of Parkinson’s disease medicines availability and affordability in Nigeria. Mov Disord Clin Pract. 2019;6(1):27–33.PubMed
28.
go back to reference GBD 2015 Neurological Disorders Collaborator Group: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Neurology 2017, 16(11):877–897. GBD 2015 Neurological Disorders Collaborator Group: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Neurology 2017, 16(11):877–897.
29.
go back to reference Fothergill-Misbah N, Maroo H, Cham M, Pezzoli G, Walker R, Cilia R. Could Mucuna pruriens be the answer to Parkinson’s disease management in sub-Saharan Africa and other low-income countries worldwide? Parkinsonism Relat Disord. 2020;73:3–7.PubMed Fothergill-Misbah N, Maroo H, Cham M, Pezzoli G, Walker R, Cilia R. Could Mucuna pruriens be the answer to Parkinson’s disease management in sub-Saharan Africa and other low-income countries worldwide? Parkinsonism Relat Disord. 2020;73:3–7.PubMed
30.
go back to reference Cilia R, Laguna J, Cassani E, Cereda E, Raspini B, Barichella M, Pezzoli G. Daily intake of Mucuna pruriens in advanced Parkinson’s disease: a 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord. 2018;49:60–6.PubMed Cilia R, Laguna J, Cassani E, Cereda E, Raspini B, Barichella M, Pezzoli G. Daily intake of Mucuna pruriens in advanced Parkinson’s disease: a 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord. 2018;49:60–6.PubMed
31.
go back to reference Okubadejo N, Britton A, Crews C, Akinyemi R, Hardy J, Singleton A, Bras J. Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. PLoS ONE. 2008;3(10): e3421.PubMedPubMedCentral Okubadejo N, Britton A, Crews C, Akinyemi R, Hardy J, Singleton A, Bras J. Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. PLoS ONE. 2008;3(10): e3421.PubMedPubMedCentral
32.
go back to reference Gurdasani D, Carstensen T, Tekola-Ayele F, Pagani L, Tachmazidou I, Hatzikotoulas K, Karthikeyan S, Iles L, Pollard MO, Choudhury A, et al. The African Genome Variation Project shapes medical genetics in Africa. Nature. 2015;517(7534):327–32.PubMed Gurdasani D, Carstensen T, Tekola-Ayele F, Pagani L, Tachmazidou I, Hatzikotoulas K, Karthikeyan S, Iles L, Pollard MO, Choudhury A, et al. The African Genome Variation Project shapes medical genetics in Africa. Nature. 2015;517(7534):327–32.PubMed
33.
go back to reference Genomics England: The National Genomic Research Library v5.1. In.: Genomics England Limited; 2020. Genomics England: The National Genomic Research Library v5.1. In.: Genomics England Limited; 2020.
34.
go back to reference Cilia R, Sironi F, Akpalu A, Cham M, Sarfo FS, Brambilla T, Bonetti A, Amboni M, Goldwurm S, Pezzoli G. Screening LRRK2 gene mutations in patients with Parkinson’s disease in Ghana. J Neurol. 2012;259(3):569–70.PubMed Cilia R, Sironi F, Akpalu A, Cham M, Sarfo FS, Brambilla T, Bonetti A, Amboni M, Goldwurm S, Pezzoli G. Screening LRRK2 gene mutations in patients with Parkinson’s disease in Ghana. J Neurol. 2012;259(3):569–70.PubMed
35.
go back to reference Rizig M, Ojo OO, Athanasiou-Fragkouli A, Agabi OP, Oshinaike OO, Houlden H, Okubadejo NU. Negative screening for 12 rare LRRK2 pathogenic variants in a cohort of Nigerians with Parkinson’s disease. Neurobiol Aging. 2021;99:101.e115-101.e119. Rizig M, Ojo OO, Athanasiou-Fragkouli A, Agabi OP, Oshinaike OO, Houlden H, Okubadejo NU. Negative screening for 12 rare LRRK2 pathogenic variants in a cohort of Nigerians with Parkinson’s disease. Neurobiol Aging. 2021;99:101.e115-101.e119.
36.
go back to reference Okubadejo NU, Rizig M, Ojo OO, Jonvik H, Oshinaike O, Brown E, Houlden H. Leucine rich repeat kinase 2 (LRRK2) GLY2019SER mutation is absent in a second cohort of Nigerian Africans with Parkinson disease. PLoS ONE. 2018;13(12): e0207984.PubMedPubMedCentral Okubadejo NU, Rizig M, Ojo OO, Jonvik H, Oshinaike O, Brown E, Houlden H. Leucine rich repeat kinase 2 (LRRK2) GLY2019SER mutation is absent in a second cohort of Nigerian Africans with Parkinson disease. PLoS ONE. 2018;13(12): e0207984.PubMedPubMedCentral
37.
go back to reference Okubadejo NU. An analysis of genetic studies of Parkinson’s disease in Africa. Parkinsonism Relat Disord. 2008;14(3):177–82.PubMed Okubadejo NU. An analysis of genetic studies of Parkinson’s disease in Africa. Parkinsonism Relat Disord. 2008;14(3):177–82.PubMed
39.
go back to reference Warner TT, Schapira AHV. Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol. 2003;53(S3):S16–25.PubMed Warner TT, Schapira AHV. Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol. 2003;53(S3):S16–25.PubMed
40.
go back to reference Dardiotis E, Xiromerisiou G, Hadjichristodoulou C, Tsatsakis AM, Wilks MF, Hadjigeorgiou GM. The interplay between environmental and genetic factors in Parkinson’s disease susceptibility: the evidence for pesticides. Toxicology. 2013;307:17–23.PubMed Dardiotis E, Xiromerisiou G, Hadjichristodoulou C, Tsatsakis AM, Wilks MF, Hadjigeorgiou GM. The interplay between environmental and genetic factors in Parkinson’s disease susceptibility: the evidence for pesticides. Toxicology. 2013;307:17–23.PubMed
41.
go back to reference Dorsey E, Bloem B. The Parkinson pandemic-a call to action. JAMA Neurol. 2018;75(1):9–10.PubMed Dorsey E, Bloem B. The Parkinson pandemic-a call to action. JAMA Neurol. 2018;75(1):9–10.PubMed
42.
go back to reference Tangamornsuksan W, Lohitnavy O, Sruamsiri R, Chaiyakunapruk N, Norman Scholfield C, Reisfeld B, Lohitnavy M. Paraquat exposure and Parkinson’s disease: a systematic review and meta-analysis. Arch Environ Occup Health. 2019;74(5):225–38.PubMed Tangamornsuksan W, Lohitnavy O, Sruamsiri R, Chaiyakunapruk N, Norman Scholfield C, Reisfeld B, Lohitnavy M. Paraquat exposure and Parkinson’s disease: a systematic review and meta-analysis. Arch Environ Occup Health. 2019;74(5):225–38.PubMed
43.
go back to reference Vaccari C, Dib R, Gomaa H, Lopes L, De Camargo JL. Paraquat and Parkinson’s disease: a systematic review and meta-analysis of observational studies. J Toxicol Environ Health B Crit Rev, Part B. 2019;22:1–31. Vaccari C, Dib R, Gomaa H, Lopes L, De Camargo JL. Paraquat and Parkinson’s disease: a systematic review and meta-analysis of observational studies. J Toxicol Environ Health B Crit Rev, Part B. 2019;22:1–31.
44.
go back to reference Chen S-J, Lin C-H. Gut microenvironmental changes as a potential trigger in Parkinson’s disease through the gut–brain axis. J Biomed Sci. 2022;29(1):54.PubMedPubMedCentral Chen S-J, Lin C-H. Gut microenvironmental changes as a potential trigger in Parkinson’s disease through the gut–brain axis. J Biomed Sci. 2022;29(1):54.PubMedPubMedCentral
45.
go back to reference Keshavarzian A, Engen P, Bonvegna S, Cilia R. The gut microbiome in Parkinson’s disease: a culprit or a bystander? Prog Brain Res. 2020;252:357–450.PubMed Keshavarzian A, Engen P, Bonvegna S, Cilia R. The gut microbiome in Parkinson’s disease: a culprit or a bystander? Prog Brain Res. 2020;252:357–450.PubMed
46.
go back to reference Herrick MK, Tansey MG. Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease? NPJ Parkinsons Dis. 2021;7(1):26.PubMedPubMedCentral Herrick MK, Tansey MG. Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease? NPJ Parkinsons Dis. 2021;7(1):26.PubMedPubMedCentral
47.
go back to reference Gorecki AM, Dunlop SA, Rodger J, Anderton RS: The gut-brain axis and gut inflammation in Parkinson’s disease: stopping neurodegeneration at the toll gate. Expert Opin Ther Targets. 2020:1–4. Gorecki AM, Dunlop SA, Rodger J, Anderton RS: The gut-brain axis and gut inflammation in Parkinson’s disease: stopping neurodegeneration at the toll gate. Expert Opin Ther Targets. 2020:1–4.
48.
go back to reference Scheperjans F, Derkinderen P, Borghammer P. The Gut and Parkinson’s Disease: hype or hope? J Parkinsons Dis. 2018;8(s1):S31–9.PubMedPubMedCentral Scheperjans F, Derkinderen P, Borghammer P. The Gut and Parkinson’s Disease: hype or hope? J Parkinsons Dis. 2018;8(s1):S31–9.PubMedPubMedCentral
49.
go back to reference Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.PubMedPubMedCentral Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.PubMedPubMedCentral
50.
go back to reference Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.PubMedPubMedCentral Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.PubMedPubMedCentral
51.
go back to reference Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.PubMedPubMedCentral Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–4.PubMedPubMedCentral
52.
53.
go back to reference Blauwendraat C, Faghri F, Pihlstrom L, Geiger JT, Elbaz A, Lesage S, Corvol J-C, May P, Nicolas A, Abramzon Y, et al. NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol Aging. 2017;57:247.e249-247.e213. Blauwendraat C, Faghri F, Pihlstrom L, Geiger JT, Elbaz A, Lesage S, Corvol J-C, May P, Nicolas A, Abramzon Y, et al. NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiol Aging. 2017;57:247.e249-247.e213.
54.
go back to reference Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, et al. Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism. Mov Disord. 2019;34(3):396–405.PubMed Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, et al. Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism. Mov Disord. 2019;34(3):396–405.PubMed
56.
go back to reference Vivacqua G, Mason M, De Bartolo MI, Węgrzynowicz M, Calò L, Belvisi D, Suppa A, Fabbrini G, Berardelli A, Spillantini M. Salivary α-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson’s Disease. Mov Disord. 2023;38(1):153–5.PubMed Vivacqua G, Mason M, De Bartolo MI, Węgrzynowicz M, Calò L, Belvisi D, Suppa A, Fabbrini G, Berardelli A, Spillantini M. Salivary α-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson’s Disease. Mov Disord. 2023;38(1):153–5.PubMed
57.
go back to reference Luan M, Sun Y, Chen J, Jiang Y, Li F, Wei L, Sun W, Ma J, Song L, Liu J, et al. Diagnostic value of salivary real-time quaking-induced conversion in Parkinson’s Disease and multiple system atrophy. Mov Disord. 2022;37(5):1059–63.PubMed Luan M, Sun Y, Chen J, Jiang Y, Li F, Wei L, Sun W, Ma J, Song L, Liu J, et al. Diagnostic value of salivary real-time quaking-induced conversion in Parkinson’s Disease and multiple system atrophy. Mov Disord. 2022;37(5):1059–63.PubMed
58.
go back to reference Morgan J. Joy of super smeller: sebum clues for PD diagnostics. Lancet Neurol. 2016;15(2):138–9.PubMed Morgan J. Joy of super smeller: sebum clues for PD diagnostics. Lancet Neurol. 2016;15(2):138–9.PubMed
59.
go back to reference Géhin C, Tokarska J, Fowler SJ, Barran PE, Trivedi DK. No skin off your back: the sampling and extraction of sebum for metabolomics. Metabolomics. 2023;19(4):21.PubMedPubMedCentral Géhin C, Tokarska J, Fowler SJ, Barran PE, Trivedi DK. No skin off your back: the sampling and extraction of sebum for metabolomics. Metabolomics. 2023;19(4):21.PubMedPubMedCentral
60.
go back to reference Morris R, Lord S, Bunce J, Burn D, Rochester L. Gait and cognition: mapping the global and discrete relationships in ageing and neurodegenerative disease. Neurosci Biobehav Rev. 2016;64:326–45.PubMed Morris R, Lord S, Bunce J, Burn D, Rochester L. Gait and cognition: mapping the global and discrete relationships in ageing and neurodegenerative disease. Neurosci Biobehav Rev. 2016;64:326–45.PubMed
61.
go back to reference Del Din S, Lewis EG, Gray WK, Collin H, Kissima J, Rochester L, Dotchin C, Urasa S, Walker R: Monitoring walking activity with wearable technology in rural-dwelling older adults in Tanzania: a feasibility study nested within a frailty prevalence study. Experimental Aging Research 2020:1–15. Del Din S, Lewis EG, Gray WK, Collin H, Kissima J, Rochester L, Dotchin C, Urasa S, Walker R: Monitoring walking activity with wearable technology in rural-dwelling older adults in Tanzania: a feasibility study nested within a frailty prevalence study. Experimental Aging Research 2020:1–15.
62.
go back to reference Palmerini L, Reggi L, Bonci T, Del Din S, Micó-Amigo ME, Salis F, Bertuletti S, Caruso M, Cereatti A, Gazit E, et al. Mobility recorded by wearable devices and gold standards: the Mobilise-D procedure for data standardization. Scientific Data. 2023;10(1):38.PubMedPubMedCentral Palmerini L, Reggi L, Bonci T, Del Din S, Micó-Amigo ME, Salis F, Bertuletti S, Caruso M, Cereatti A, Gazit E, et al. Mobility recorded by wearable devices and gold standards: the Mobilise-D procedure for data standardization. Scientific Data. 2023;10(1):38.PubMedPubMedCentral
63.
go back to reference Packer E, Debelle H, Bailey HGB, Ciravegna F, Ireson N, Evers J, Niessen M, Shi JQ, Yarnall AJ, Rochester L, et al. Translating digital healthcare to enhance clinical management: a protocol for an observational study using a digital health technology system to monitor medication adherence and its effect on mobility in people with Parkinson’s. BMJ Open. 2023;13(9): e073388.PubMedPubMedCentral Packer E, Debelle H, Bailey HGB, Ciravegna F, Ireson N, Evers J, Niessen M, Shi JQ, Yarnall AJ, Rochester L, et al. Translating digital healthcare to enhance clinical management: a protocol for an observational study using a digital health technology system to monitor medication adherence and its effect on mobility in people with Parkinson’s. BMJ Open. 2023;13(9): e073388.PubMedPubMedCentral
64.
go back to reference Del Din S, Galna B, Godfrey A, Bekkers EMJ, Pelosin E, Nieuwhof F, Mirelman A, Hausdorff JM, Rochester L. Analysis of free-living gait in older adults with and without Parkinson’s Disease and with and without a history of falls: identifying generic and disease-specific characteristics. J Gerontol A Biol Sci Med Sci. 2019;74(4):500–6.PubMed Del Din S, Galna B, Godfrey A, Bekkers EMJ, Pelosin E, Nieuwhof F, Mirelman A, Hausdorff JM, Rochester L. Analysis of free-living gait in older adults with and without Parkinson’s Disease and with and without a history of falls: identifying generic and disease-specific characteristics. J Gerontol A Biol Sci Med Sci. 2019;74(4):500–6.PubMed
65.
go back to reference Smits EJ, Tolonen AJ, Cluitmans L, van Gils M, Zietsma RC, Tijssen MAJ, Maurits NM. Reproducibility of standardized fine motor control tasks and age effects in healthy adults. Measurement. 2018;114:177–84. Smits EJ, Tolonen AJ, Cluitmans L, van Gils M, Zietsma RC, Tijssen MAJ, Maurits NM. Reproducibility of standardized fine motor control tasks and age effects in healthy adults. Measurement. 2018;114:177–84.
66.
go back to reference Smits EJ, Tolonen AJ, Cluitmans L, van Gils M, Zietsma RC, Borgemeester RW, van Laar T, Maurits NM. Graphical tasks to measure upper limb function in patients with Parkinson’s Disease: validity and response to dopaminergic medication. IEEE J Biomed Health Inform. 2017;21(1):283–9.PubMed Smits EJ, Tolonen AJ, Cluitmans L, van Gils M, Zietsma RC, Borgemeester RW, van Laar T, Maurits NM. Graphical tasks to measure upper limb function in patients with Parkinson’s Disease: validity and response to dopaminergic medication. IEEE J Biomed Health Inform. 2017;21(1):283–9.PubMed
67.
go back to reference Lee JY, Ahn J, Oh S, Shin JY, Kim YK, Nam H, Jeon B. Retina thickness as a marker of neurodegeneration in prodromal lewy body disease. Mov Disord. 2020;35(2):349–54.PubMed Lee JY, Ahn J, Oh S, Shin JY, Kim YK, Nam H, Jeon B. Retina thickness as a marker of neurodegeneration in prodromal lewy body disease. Mov Disord. 2020;35(2):349–54.PubMed
68.
go back to reference Lee JY, Ahn J, Kim TW, Jeon BS. Optical coherence tomography in Parkinson’s disease: is the retina a biomarker? J Parkinsons Dis. 2014;4(2):197–204.PubMed Lee JY, Ahn J, Kim TW, Jeon BS. Optical coherence tomography in Parkinson’s disease: is the retina a biomarker? J Parkinsons Dis. 2014;4(2):197–204.PubMed
69.
go back to reference Kafieh R, Rakhshani S, Hogg J, Lawson RA, Pavese N, Innes W, Steel DH, Bacardit J, Read J, Hurlbert A: A robust, flexible retinal segmentation algorithm designed to handle neuro-degenerative disease pathology (NDD-SEG). Investigative Ophthalmology & Visual Science 2022, 63(7):2080 – F0069–2080 – F0069. Kafieh R, Rakhshani S, Hogg J, Lawson RA, Pavese N, Innes W, Steel DH, Bacardit J, Read J, Hurlbert A: A robust, flexible retinal segmentation algorithm designed to handle neuro-degenerative disease pathology (NDD-SEG). Investigative Ophthalmology & Visual Science 2022, 63(7):2080 – F0069–2080 – F0069.
70.
go back to reference Wagner SK, Hughes F, Cortina-Borja M, Pontikos N, Struyven R, Liu X, Montgomery H, Alexander DC, Topol E, Petersen SE, et al. AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK. BMJ Open. 2022;12(3): e058552.PubMedPubMedCentral Wagner SK, Hughes F, Cortina-Borja M, Pontikos N, Struyven R, Liu X, Montgomery H, Alexander DC, Topol E, Petersen SE, et al. AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK. BMJ Open. 2022;12(3): e058552.PubMedPubMedCentral
71.
go back to reference Arora S, Baig F, Lo C, Barber TR, Lawton MA, Zhan A, Rolinski M, Ruffmann C, Klein JC, Rumbold J, et al. Smartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD. Neurology. 2018;91(16):e1528–38.PubMedPubMedCentral Arora S, Baig F, Lo C, Barber TR, Lawton MA, Zhan A, Rolinski M, Ruffmann C, Klein JC, Rumbold J, et al. Smartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD. Neurology. 2018;91(16):e1528–38.PubMedPubMedCentral
72.
go back to reference Lo C, Arora S, Baig F, Lawton MA, El Mouden C, Barber TR, Ruffmann C, Klein JC, Brown P, Ben-Shlomo Y, et al. Predicting motor, cognitive & functional impairment in Parkinson’s. Ann Clin Transl Neurol. 2019;6(8):1498–509.PubMedPubMedCentral Lo C, Arora S, Baig F, Lawton MA, El Mouden C, Barber TR, Ruffmann C, Klein JC, Brown P, Ben-Shlomo Y, et al. Predicting motor, cognitive & functional impairment in Parkinson’s. Ann Clin Transl Neurol. 2019;6(8):1498–509.PubMedPubMedCentral
73.
go back to reference Martinez-Martin P, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Chaudhuri KR. Group obotINMPS: Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS). Mov Disord Clin Pract. 2019;6(3):227–34.PubMedPubMedCentral Martinez-Martin P, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Chaudhuri KR. Group obotINMPS: Pilot Study of the International Parkinson and Movement Disorder Society-sponsored Non-motor Rating Scale (MDS-NMS). Mov Disord Clin Pract. 2019;6(3):227–34.PubMedPubMedCentral
74.
go back to reference Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.PubMed Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.PubMed
75.
go back to reference Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, de Pedro J. The clinical impression of severity index for Parkinson’s disease: International validation study. Mov Disord. 2009;24(2):211–7.PubMed Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, de Pedro J. The clinical impression of severity index for Parkinson’s disease: International validation study. Mov Disord. 2009;24(2):211–7.PubMed
76.
go back to reference Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Mov Disord. 2007;22(13):1901–11.PubMed Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, et al. The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: Results from an international pilot study. Mov Disord. 2007;22(13):1901–11.PubMed
77.
go back to reference Mahoney FI, Barthel DW. Functional evaluation: the barthel index. Md State Med J. 1965;14:61–5.PubMed Mahoney FI, Barthel DW. Functional evaluation: the barthel index. Md State Med J. 1965;14:61–5.PubMed
78.
go back to reference Gray WK, Paddick S-M, Kisoli A, Dotchin CL, Longdon AR, Chaote P, Samuel M, Jusabani AM, Walker RW. Development and validation of the identification and Intervention for Dementia in Elderly Africans (IDEA) study dementia screening instrument. J Geriatr Psychiatry Neurol. 2014;27(2):110–8.PubMed Gray WK, Paddick S-M, Kisoli A, Dotchin CL, Longdon AR, Chaote P, Samuel M, Jusabani AM, Walker RW. Development and validation of the identification and Intervention for Dementia in Elderly Africans (IDEA) study dementia screening instrument. J Geriatr Psychiatry Neurol. 2014;27(2):110–8.PubMed
79.
go back to reference Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form parkinson’s disease questionnaire. Psychol Health. 1997;12(6):805–14. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form parkinson’s disease questionnaire. Psychol Health. 1997;12(6):805–14.
80.
go back to reference Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.PubMedPubMedCentral Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.PubMedPubMedCentral
81.
go back to reference Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument. Mov Disord. 2007;22(16):2386–93.PubMed Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument. Mov Disord. 2007;22(16):2386–93.PubMed
82.
go back to reference Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–70.PubMed Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361–70.PubMed
83.
go back to reference Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.PubMed Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.PubMed
84.
go back to reference Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, Pezzela FR, Forbes A, Högl B, Trenkwalder C. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):629–35.PubMedPubMedCentral Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, Pezzela FR, Forbes A, Högl B, Trenkwalder C. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):629–35.PubMedPubMedCentral
85.
go back to reference Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5.PubMed Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5.PubMed
86.
go back to reference Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord. 2009;24(10):1461–7.PubMedPubMedCentral Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord. 2009;24(10):1461–7.PubMedPubMedCentral
87.
go back to reference Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson’s disease: The SCOPA-AUT. Mov Disord. 2004;19(11):1306–12.PubMed Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson’s disease: The SCOPA-AUT. Mov Disord. 2004;19(11):1306–12.PubMed
88.
go back to reference Mathur S, LaMonica K, Matthews H, Hill K. Self-image in women with Parkinson’s Disease. J Parkinsons Dis. 2023;13(3):329–32.PubMedPubMedCentral Mathur S, LaMonica K, Matthews H, Hill K. Self-image in women with Parkinson’s Disease. J Parkinsons Dis. 2023;13(3):329–32.PubMedPubMedCentral
89.
go back to reference Wimo A, Jonsson L, Zbrozek A. The resource utilization in dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia. J Nutr Health Aging. 2010;14(8):685–90.PubMed Wimo A, Jonsson L, Zbrozek A. The resource utilization in dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia. J Nutr Health Aging. 2010;14(8):685–90.PubMed
90.
go back to reference Cubo E, Delgado-López PD. Telemedicine in the management of Parkinson’s Disease: achievements, challenges, and future perspectives. Brain Sci. 2022;12(12):1735.PubMedPubMedCentral Cubo E, Delgado-López PD. Telemedicine in the management of Parkinson’s Disease: achievements, challenges, and future perspectives. Brain Sci. 2022;12(12):1735.PubMedPubMedCentral
91.
go back to reference Duker AP: Video recording in movement disorders: practical issues. Continuum (Minneap Minn) 2013, 19(5 Movement Disorders):1401–1405. Duker AP: Video recording in movement disorders: practical issues. Continuum (Minneap Minn) 2013, 19(5 Movement Disorders):1401–1405.
92.
go back to reference Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.PubMed Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601.PubMed
93.
go back to reference Hoehn M, Yahr M. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17(5):427–42.PubMed Hoehn M, Yahr M. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17(5):427–42.PubMed
94.
95.
go back to reference Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351(24):2498–508.PubMed Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351(24):2498–508.PubMed
96.
go back to reference Fothergill-Misbah N, Moffatt S, Mwithiga H, Hampshire K, Walker R: The role of support groups in the management of Parkinson’s disease in Kenya: Sociality, information and legitimacy. Global Public Health 2021:1–11. Fothergill-Misbah N, Moffatt S, Mwithiga H, Hampshire K, Walker R: The role of support groups in the management of Parkinson’s disease in Kenya: Sociality, information and legitimacy. Global Public Health 2021:1–11.
97.
go back to reference Braun V, Clarke V. Thematic Analysis: A Practical Guide. United Kingdom: SAGE Publications; 2021. Braun V, Clarke V. Thematic Analysis: A Practical Guide. United Kingdom: SAGE Publications; 2021.
Metadata
Title
Transforming Parkinson's Care in Africa (TraPCAf): protocol for a multimethodology National Institute for Health and Care Research Global Health Research Group project
Authors
R. Walker
N. Fothergill-Misbah
S. Kariuki
O. Ojo
R. Cilia
M. C. J. Dekker
O. Agabi
A. Akpalu
F. Amod
M. Breckons
M. Cham
S. Del Din
C. Dotchin
S. Guggsa
J. Kwasa
D. Mushi
F. O. Nwaokorie
T. Park
L. Rochester
J. Rogathi
F. S. Sarfo
A. Shalash
L. Ternent
S. Urasa
N. Okubadejo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03414-0

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue